BenevolentAI
AI for faster drug discovery
London, UK
BenevolentAI, founded in 2013 and headquartered in London, United Kingdom, is a drug discovery company that was delisted from Euronext Amsterdam and merged with Osaka Holdings S.à r.l. on March 13, 2025, transitioning to private ownership.
Only accessible to MedStartr community members.
Join nowHow We Help
Problem Statement
The inefficiency and slowness of traditional drug discovery and development processes, hindering the rapid delivery of effective treatments to patients.
Core Technology
Benevolent Platform™ - an end-to-end computational and experimental platform for drug discovery, combining advanced AI, machine learning, and computational biology to create a comprehensive bioscience knowledge graph.
Key Differentiators
End-to-end AI-enabled drug discovery platform (Benevolent Platform™); Integration of AI and human expertise; Comprehensive bioscience knowledge graph for novel target identification; Clinical-stage pipeline and validated approach (e.g., repurposed drug candidate for COVID-19); Strategic collaborations with major pharmaceutical companies; Disease-agnostic platform applicable across any disease area.
Clinical Focus
Drug Discovery and Development
Target Customers
Pharmaceutical companies
Product Stage
GA/Mature (knowledge exploration tools); Clinical-stage (drug pipeline)
Company Info
- Business Model
- B2B (collaborations with pharmaceutical companies, commercializing knowledge exploration tools), In-house drug development (advancing own drug pipeline).
- Founded
- 2013
- Total Funding
- Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now - Website
- benevolent.ai
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Has a clinical-stage pipeline and a validated approach, exemplified by a repurposed drug candidate for COVID-19.
Only accessible to MedStartr community members.
Join nowWhat do you think of BenevolentAI?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now